CLL.L Regulatory News (CLL)

For immediate release 14 May 2013

Cello Group plc

 (the "Company" or the "Group")

Board Appointment

Cello Group plc (AIM: CLL), the insight and strategic marketing group is pleased to announce the appointment of Stephen Highley to the Board as Group Corporate Development Director.

Stephen Highley is a co-founder of MSI, a strategy consulting firm acquired by Cello in 2007 and which is now a core component of Cello Health, the Group's specialist healthcare division. Since 2012, Stephen has also been Chairman of Cello Health.

Cello Group's strategy is to expand through a mixture of accelerated organic growth and selected acquisition. As Group Corporate Development Director, Stephen will share responsibility for helping drive this process from a Board level.

Mark Scott, Cello CEO, commented; "We are delighted that Stephen is joining the Board at this time. The Group has a solid foundation from which to expand internationally in its chosen areas of focus, and Stephen will make a big difference to the rate at which we can achieve this."

Under schedule 2, paragraph (g) of the AIM rules, the following additional information is disclosed:

- Mr Highley has a beneficial interest in 2,000,868 ordinary shares of 10 pence each in the Company, which represents 2.42 per cent. of the Company's current issued ordinary share capital.

- Prior to his appointment to the board of the Group, Mr Highley did not hold any active directorships. Mr Highley has within the past 5 years been a director of MSI Consulting Ltd; Mash Health Ltd.

There are no other matters to be announced under paragraph (g) of Schedule 2 of the AIM Rules.

Enquiries: